Clone:
REA263
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Alternative names:
gp150, Myeloid plasma membrane glycoprotein CD13, Microsomal aminopeptidase, Alanyl aminopeptidase, Aminopeptidase N

Specifications for CD13 antibodies

Overview

REA263 recognizes the CD13 antigen, a 150–170 kDa type II transmembrane glycoprotein, which is also known as aminopeptidase N or gp150. CD13 is expressed on granulocytes, myeloid progenitors, endothelial cells, epithelial cells, and subset of granular lymphoid cells. It is also broadly expressed in other tissues such as kidney proximal tubules, intestine, and placenta. CD13 is an enzyme that is used as a biomarker to detect damage to the kidneys, and that may be used to help diagnose certain kidney disorders. It also serves as a receptor for one strain of human coronavirus that is an important cause of upper respiratory tract infections. Defects in CD13 appear to be a cause of various types of leukemia or lymphoma. Additional information: Clone REA263 displays negligible binding to Fc receptors.

Alternative names

gp150, Myeloid plasma membrane glycoprotein CD13, Microsomal aminopeptidase, Alanyl aminopeptidase, Aminopeptidase N

Detailed product information

Technical specifications

CloneREA263
Isotyperecombinant human IgG1
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD13
Alternative names of antigengp150, Myeloid plasma membrane glycoprotein CD13, Microsomal aminopeptidase, Alanyl aminopeptidase, Aminopeptidase N
Molecular mass of antigen [kDa]109
Distribution of antigengranulocytes, endothelial cells, epithelial cells

Resources for CD13 antibodies

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD13 antibodies

Publications

  1. Look, A. T. et al. (1989) Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J. Clin. Invest. 83(4): 1299-1307
  2. Favaloro, E. J. et al. (1993) CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp. Hematol. 21(13): 1695-1701
  3. Yeager, C. L. et al. (1992) Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 357(6377): 420-422
  4. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
  5. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
  6. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
  7. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
  8. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
  9. Wood BL et al. (2007) 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin. Cytom. 72: 14-22